Traders work the floor of the New York Stock Exchange.
NYSE
Value stocks have been on a tear in the last week after positive vaccine news from Pfizer and BioNTech raised hope of the U.S. economy staging a fast recovery next year. However, investors loading up on beaten-down value names should brace for some volatile swings as risks to the group linger.
The iShares Russell 1000 Value ETF (IWD) rallied 5.7% last week after Pfizer and BioNTech said Monday that their coronavirus vaccine candidate was more than 90% effective at preventing the coronavirus during a late-stage trial. Value’s gain came at the expense of high-flying growth stocks. The iShares Russell 1000 Growth ETF (IWF) lost 1.2% last week.
An effective vaccine could be the turning point for value stocks, but perhaps not just yet
Options traders should bet on these holiday shopping plays, Goldman says
Investment manager shares his strategy for a ‘very, very nice’ return
Goldman sees the S&P 500 rallying to 4,300 by end of 2021 on vaccine, divided government
Tom Lee says the market is about to send a major ‘risk on’ signal
MORE IN INVESTING TRENDS
Stocks like Marriott and Planet Fitness should thrive as a Covid vaccine arrives, analysts say
Michael Bloom
Tom Lee says the market is about to send a major ‘risk on’ signal
Maggie Fitzgerald
These stocks have the most to gain from a vaccine, according to UBS analysis
Yun Li
